Just like 180 days exclusivity and its forfeiter in US, SPC is the matter in EU that always lead to a critical analysis and interpretation of such legislation. Recently Antwerp Court of Appeal has decided in a case of Novartis v Teva, case 2010/RK/456 on 9 february 2011. Court ordered to stop launching of generic version of Co-diovan due to existance of SPC of this combination. I got this details from SPC blog and they have provided translated case details that you can read from here.
No comments:
Post a Comment